Summary Although case-oriented evidence for an association of Epstein-Barr virus (EBV) with 
Epstein -Barr virus (EBV) is a ubiquitous human herpes virus, closely associated with the genesis of Burkitt's lymphoma (BL), undifferentiated nasopharyngeal carcinoma (NPC) and opportunistic lymphomas in immunocompromised hosts (Liebowitz and Kieff, 1993) . Recent studies demonstrated that EBV is also implicated in Hodgkin's disease (HD) (Herbst et al., 1991; Pallesen et al., 1991) , certain T-cell lymphomas (Harabuchi et al., 1990; Su et al., 1991; Korbjuhn et al., 1993) and thymic carcinoma (Leyvraz et al., 1985; Dimery et al., 1988; Patton et al., 1994) . All or a significant proportion of neoplastic cells of the tumours harbour EBV DNA and express virus-coded latent infection (immortalisation-associated) proteins. Some of these EBVrelated malignancies have been precisely analysed for viral latent gene expression and show characteristic patterns for each individual tumour (Liebowitz and Kieff, 1993) .
Over ten major EBV genes are known to be potentially transcribed in cells latently infected with the virus: EBV nuclear antigens (EBNA) 1, -2, -3A, -3B, -3C and leader protein (LP); latent membrane proteins (LMP) 1, -2A, and -2B; untranslated EBV-encoded small RNAs (EBER)-1 and -2 (Liebowitz and ; and a recently found transcript containing the BamHI-A rightward open reading frame (BARFO) (Gilligan et al., 1990) . All the latent transcripts are regularly expressed in in vitro EBV-immortalised Blymphoblastoid cell lines (LCL) and some B lymphoproliferative disorders occurring in immunosuppressed patients (latency III) (Young et al., 1989; Kerr et al., 1992) . In contrast, only EBERs, EBNA1 and BamHI-A transcripts are expressed in most in vivo BL cells and several BL cell lines (latency I), which are referred to as group I BL cells (Rowe et al., 1987; Brooks et al., 1993) ; and three LMP genes are additionally expressed along with EBERs, EBNA1 and BamHI-A RNAs in the majority of NPC and HD (latency II) cases (Kerr et al., 1992; Deacon et al., 1993) .
Furthermore, the combination of EBNA mRNA expressed depends on which of three mutually exclusive EBNA promoters, BamHI-C, -W and -Q promoters (Cp, Wp and Qp respectively), is active. The Cp-or Wp-initiated large primary transcript is differentially spliced into all six EBNA mRNAs as is seen in cells with latency III (e.g LCL) (Rogers et al., 1990) , whereas Qp mediates the selective expression of only EBNA1 mRNA through bypassing coding regions of the other EBNA genes, consequently leading to the complete lack of EBNA2, -3A, -3B, -3C and -LP mRNAs represented by group I BL and NPC cells (Schaefer et al., 1995a; Nonkwelo et al., 1996) .
Gastric carcinoma, the most common malignancy in Japan, is being recognised as one of the EBV-related tumours (Shibata et al., 1991; Imai et al., 1994) . Although our previous work revealed that about 7% of Japanese gastric carcinomas were EBV genome-positive and that, in addition to EBERs, EBNA1, but not the other EBNAs or LMP1, protein was expressed in the tumour cells (Imai et al., 1994) , details about expression of the other latent genes, LMP2A, -2B and BARFO, and about utilisation of an EBNA promoter, which is also necessary to understand the EBVinduced oncogenic process, are still unknown. In this study, we analysed seven EBV-positive gastric carcinomas more extensively for virus latent and replication cycle gene expression together with EBNA promoter usage at the mRNA level, using the reverse transcription -polymerase chain reaction (RT-PCR) technique.
Materials and methods Subjects
Tumour tissues used in this study were resected or endoscopically biopsied from the stomachs of seven patients with EBV-positive gastric carcinoma and six patients with EBV-negative gastric carcinoma. The clinical and histological data of the patients with EBV-positive gastric carcinoma are shown in Table I (Countryman et al., 1987) , B95-8 cells (Miller and Lipman, 1973) EBV gene expression in gastric carcinoma M Sugiura et al heating at 95°C, RNA was ethanol-precipitated again, then resuspended in DEPC-treated water and dispensed into small aliquots. To test the sensitivity of our RT-PCR system, RNA was prepared from 106 appropriate control cells, serially 10-fold diluted from a quantity equivalent to 105 to 100 cells, and the total RNA amount of each diluted sample was adjusted to that of 105 cells by addition of RNA extracted from BJAB cells. For cDNA synthesis, 10 pmol of a 3'-primer specific for each transcript (Table II) was added to the RNA sample, followed by heating at 94°C for 5 min and rapid chilling on ice. Reagents were added to the RNAprimer mixture to give a final concentration of 50 mM Tris-HCI (pH 8.3), 75 mM potassium chloride, 3 mM magnesium chloride, 10 mM dithiothreitol, 0.5 mm for each dNTP, 10 U of RNasin (Promega, Madison, WI, USA) and 200 U of Molony murine leukaemia virus reverse transcriptase (Gibco BRL). Reverse transcription was performed at 37°C for 60 min in a total volume of 20 pl and then heated at 940C for 3 min to stop the reaction.
PCR and detection of amplified products
Full details of the sequences and genome coordinates of primers and probes used to detect EBV transcripts are given in Table II 273 bp m cDNA, in a total volume of 100 pl. After it was overlaid with mineral oil, the reaction mixture was heated to 94°C for 3 min, slowly cooled to 70°C, and then 2.5 U of Taq polymerase (Gibco BRL) was added to the tubes. Samples were then subjected to 35 cycles of amplification by a Thermal Cycler 480 (Perkin-Elmer, Foster City, CA, USA), each cycle consisting of 94°C for 1 min (denaturation), 45°C for 2 min (annealing) and 72°C for 3 min (DNA extension). The extension time was prolonged to 6 min in the last cycle. The quality of RNA preparations was simultaneously checked by 30 cycles of amplification of cytoplasmic fl-actin mRNA with the antisense primer (5'-GGAGCAAT-GATCTTGATCTTC-3') and the sense primer (5'-CCTTCCTGGGCATGGAGTCCT-3') (Busson et al., 1992) . The PCR products were electrophoresed in 1.5% agarose gels (SeaKem; Takara, Otsu, Japan), stained with ethidium bromide (Et-Br), and photographed under a UV-transilluminator. They were denatured in an alkali solution for 20 min with gentle rocking and directly blotted onto nylon membranes (Biodyne-B; Pall, Glen Cove, NY, USA) by vacuum transfer. The blotted membranes were fixed with a UV-crosslinker (Bio Rad, Richmond, CA, USA) and then subjected to hybridisation with [y-32P]ATP-5'-end-labelled internal oligonucleotide probes. The exposure time of autoradiograph was 6-12 h for viral transcripts and 2 h for ,B-actin mRNA.
Immunofluorescence assay
Frozen tissue sections of EBV-positive gastric carcinomas were examined for expression of the BZLF1 protein by streptavidin-biotin immunofluorescence, using mouse BZ.1 (Figure 1) . The results were consistent with our previous observations at the protein level (Imai et al., 1994) . We further investigated expression of LMP2A, -2B and BamHI-A transcripts in EBV-positive gastric carcinoma, which remain unknown so far. As shown in Figure 2 , LMP2A mRNA was detected in three of the seven cases, although LMP2B mRNA was undetectable in all cases. Transcripts from the BamHI-A fragment of the virus genomes were also detected in all seven cases studied ( Figure 2 ). Based on the above results, the EBV latent gene expression pattern in gastric carcinoma is delineated in (Figure 3 ). It is unlikely that the Q/U/K exon-containing EBNA1 transcript detected here was initiated from the BamHI-F promoter (Fp), which was initially reported to be a third EBNA promoter (Schaefer et al., 1991; Sample et al., 1991) and redefined thereafter as an early lytic promoter (Lear et al., 1992; (Shimizu et al., 1994) . Accordingly, since EBNA1, the putative BamHI-A product and EBERs are commonly expressed both in group I BL and in gastric carcinoma cells, they may also be responsible, to some extent, for the malignant features of gastric carcinoma. Recently a possible role for EBNA1 in the EBV-induced oncogenic process has been proposed in that its Gly-Ala repetitive sequence inhibited the specific cytotoxic T-cell recognition of immunodominant EBNA3B through a cis-acting mode (Levitskaya et al., 1995) . Several in vitro studies, however, demonstrated that LMP1 potentially confers tumorigenicity on non-lymphoid cells via transformation of established rodent fibroblasts (Wang et al., 1985) and human keratinocytes (Fahraeus et al., 1990) , inhibition of human epithelial cell differentiation (Dawson et al., 1990) , and induction of the functional epidermal growth factor receptor (Miller et al., 1995) . Such important findings strongly support crucial roles for LMP1 in the development of undifferentiated NPC, where the LMP1 positivity exceeds 80% of the cases at the trancriptional level Chen et al., 1995) . The exact lack of LMP1 expression in EBV-positive gastric carcinomas, irrespective of their histological phenotypes, implies that LMP1 may not be necessary for the tumour, at least to sustain its already established malignant state. Rather, LMP1 might participate in an earlier stage of the tumour development and be down-regulated thereafter. Alternatively, the lack of LMP1 may reflect the result of (Khanna et al., 1992; Murray et al., 1992) . In fact, patients with EBV-positive gastric carcinoma have normally retained virus-specific immune T-cell responses (Imai et al., 1994) as is the case with BL (Rooney et al., 1985) , in contrast to NPC patients (Moss et al., 1983) . The EBV replication can be switched on in malignant or non-malignant epithelial proliferative lesions in vivo; the immediate-early BZLF1, the early and/or late antigens were detected in NPC (Cochet et al., 1993) , thymic carcinoma (Patton et al., 1994) and AIDS-associated oral hairy leucoplakia (OHL) (Greenspan et al., 1985) . Similar viral cycle events were also observed in vitro by experimental EBV infection of cells of epithelial origin (Li et al., 1992; Sixbey and Yao, 1992) . There is a report of a patient with EBVpositive undifferentiated gastric carcinoma, in which a very small proportion of tumour cells expressed the BZLF1 protein, indicating that rare gastric carcinoma cells can potentially enter the lytic cycle . The present study in contrast, showed that neither the BZLF1 mRNA nor protein was found in gastric carcinoma tissues, results compatible with the absence of the early and viral capsid antigens as previously reported (Imai et al., 1994) . In addition, although EBV latency can be disrupted as epithelial cells differentiate, as shown by observations in OHL , none of the gastric carcinomas with various differentiations showed any evidence of virus production. LMP2A, detectably expressed in three of our seven cases, was shown to block calcium mobilisation in B cells, thereby suppressing EBV replication (Miller et al., 1993 (Miller et al., , 1994 . It is unknown whether the finding can be extended to epithelial cells; however, at least in certain EBV-positive gastric carcinomas, the absence of tumour cells entering the lytic cycle may be associated with LMP2A expression. It was inferred from our series of data that, unlike in NPC or OHL cells, virus replication was uncommon or abortive in gastric carcinoma, and that the vast majority of tumour cells carried EBV in a tightly latent fashion.
The strict localisation of EBV genomes and viral gene expression only in tumour cells and their monoclonality (Oda et al., 1993; Imai et al., 1994 ) strongly suggest that EBV may be indeed involved, not a passenger, in the development of virus-positive gastric carcinoma, although several questions remain to be resolved. Further studies are necessary to understand more direct oncogenic activities of EBV on normal gastric mucosal epithelia and a factor(s) enhancing them.
